Karus CEO highlights niche indications for oncology innovation

November 24, 2016 Christoph Graener

 

Karus Therapeutics CEO, Simon Kerry, talks to Scrip senior writer, Lucie Ellis, during the recent BIO-Europe® partnering meeting about the company’s cancer-focused pipeline and where its products will sit within the crowded oncology market space. Kerry highlights Karus’ strategy of targeting niche cancer indications and outlines how the smaller biotech will compete with big pharma businesses active in oncology drug development.

  

  

Interviewer: Lucie Ellis – Senior Writer, Pharma Intelligence In Vivo/Pink Sheet/Scrip
Interviewee: Simon Kerry – CEO, Karus Therapeutics

 

 

Previous Article
AiCuris seeks partners for antibacterial programs
AiCuris seeks partners for antibacterial programs

AiCuris CEO Holger Zimmermann talks about the company's journey to becoming a clinical biotech company sinc...

Next Article
Cinfa outlines biosimilar development areas and deal opportunities
Cinfa outlines biosimilar development areas and deal opportunities

Cinfa Biotech's managing director, Ruediger Jankowsky, discusses the company's founding and focus on biosim...